Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2
5(71.4%)
Phase 1
2(28.6%)
7Total
Phase 2(5)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06921317Phase 1Recruiting

GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma

Role: lead

NCT07140380Phase 2Completed

Phase 2b Controlled Study

Role: lead

NCT07161011Phase 2Completed

Phase 2b Controlled Study of Dosing Techniques - Part B

Role: lead

NCT06400459Phase 1Completed

IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease

Role: lead

NCT05816070Phase 2Completed

Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial Conjunctivitis

Role: lead

NCT03749317Phase 2Completed

Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis

Role: lead

NCT06463678Phase 2Not Yet Recruiting

Trial to Evaluate the Efficacy And Safety of IVIEW-1201 In the Treatment of Fungal Keratitis

Role: lead

All 7 trials loaded